~~<i id='7C5054B3F2'><strike id='7C5054B3F2'><tt id='7C5054B3F2'><pre id='7C5054B3F2'></pre></tt></strike></i>~~

Home» knowledge» knowledge

knowledge

author：explore 2025-10-01 17:08:57 Page View：7915

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper
Next article： Guidelines to prevent youth baseball injuries need more muscle

leisure time

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

Adidas to release second batch of Yeezy sneakers after breakup with Ye

FILE-YeezyshoesmadebyAdidasaredisplayedatLacedUp,asneakerresalestore,inParamus,N.J.,onOct.25,2022.Ad

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Poland's lawmakers approve a divisive law on Russian influence

FILE-Poland'slawmakersvoteinparliament,inWarsaw,Poland,onMay26,2023.Poland'slawmakershavevotedtoappr